Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Cabre

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
The Lancet. Neurology|July 11, 2014
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative studyAdipong Brickshawana, Shannon R Hinson, Michael F Romero, et al.
Annals of Neurology|February 19, 2016
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrumEoin P Flanagan, Philippe Cabre, Brian G Weinshenker, et al.
Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 12, 2022
Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSDJiraporn Jitprapaikulsan, James P Fryer, Masoud Majed, et al.
Journal of the Neurological Sciences|March 23, 2016
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled studyLaure Peyro Saint Paul, Christian Creveuil, Olivier Heinzlef, et al.
Neurology|June 21, 2015
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M Wingerchuk, Brenda Banwell, Jeffrey L Bennett, et al.
Nature Genetics|September 28, 2005
A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibilityDavid Reich, Nick Patterson, Philip L De Jager, et al.
JAMA Neurology|February 12, 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisNail Benallegue, Fabien Rollot, Sandrine Wiertlewski, et al.
Neurology|January 31, 2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational studyLaetitia Barbin, Chloe Rousseau, Natacha Jousset, et al.
Multiple Sclerosis and Related Disorders|June 25, 2021
Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residenceRicardo Soares-Dos-Reis, Jessica Li Tsz-Ching, Su-Hyun Kim, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
The Lancet. Neurology|July 11, 2014
Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative studyAdipong Brickshawana, Shannon R Hinson, Michael F Romero, et al.
Annals of Neurology|February 19, 2016
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrumEoin P Flanagan, Philippe Cabre, Brian G Weinshenker, et al.
Archives of Neurology|October 10, 2007
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJérôme de Seze, Marc Debouverie, Hélène Zephir, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 12, 2022
Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSDJiraporn Jitprapaikulsan, James P Fryer, Masoud Majed, et al.
Journal of the Neurological Sciences|March 23, 2016
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled studyLaure Peyro Saint Paul, Christian Creveuil, Olivier Heinzlef, et al.
Neurology|June 21, 2015
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M Wingerchuk, Brenda Banwell, Jeffrey L Bennett, et al.
Nature Genetics|September 28, 2005
A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibilityDavid Reich, Nick Patterson, Philip L De Jager, et al.
JAMA Neurology|February 12, 2024
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple SclerosisNail Benallegue, Fabien Rollot, Sandrine Wiertlewski, et al.
Neurology|January 31, 2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational studyLaetitia Barbin, Chloe Rousseau, Natacha Jousset, et al.
Multiple Sclerosis and Related Disorders|June 25, 2021
Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residenceRicardo Soares-Dos-Reis, Jessica Li Tsz-Ching, Su-Hyun Kim, et al.
Pageof 8